The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Phase II Trial of Bevacizumab Plus Gemcitabine in Patients With Advanced Pancreatic Cancer
Abstract
Purpose: Vascular endothelial growth factor (VEGF) plays a key role in the biology and prognosis of pancreatic cancer. Inhibitors of VEGF suppress the growth of pancreatic cancer in preclinical models. The objectives of this phase II study were to assess the response rate and overall survival of pancreatic cancer patients who received gemcitabine with the recombinant humanized anti-VEGF monoclonal antibody bevacizumab. Patients and Methods: Patients with previously untreated advanced pancreatic cancer received gemcitabine 1,000 mg/m 2 intravenously over 30 minutes on days 1, 8, and 15 every 28 days. Bevacizumab, 10 mg/kg, was administered after gemcitabine on days 1 and 15. Tumor measurements were assessed every two cycles. Plasma VEGF levels were obtained pretreatment. Results: Fifty-two patients were enrolled at seven centers between November 2001 and March 2004. All patients had metastatic disease, and 83% had liver metastases. Eleven patients (21%) had confirmed partial responses, and 24 (46%) had stable disease. The 6-month survival rate was 77%. Median survival was 8.8 months; median progression-free survival was 5.4 months. Pretreatment plasma VEGF levels did not correlate with outcome. Grade 3 and 4 toxicities included hypertension in 19% of the patients, thrombosis in 13%, visceral perforation in 8%, and bleeding in 2%. Conclusion: The combination of bevacizumab plus gemcitabine is active in advanced pancreatic cancer patients. Additional study is warranted. A randomized phase III trial of gemcitabine plus bevacizumab versus gemcitabine plus placebo is ongoing in the Cancer and Leukemia Group B.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Burris, H. A., Moore, M. J., Andersen, J., Green, M. R., Rothenberg, M. L., Modiano, M. R., Cripps, M. C., Portenoy, R. K., Storniolo, A. M., Tarassoff, P., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.6.2403 · Cited by 5,894
Jemal, A., Tiwari, R. C., Murray, T., Ghafoor, A., Samuels, A., Ward, E., Feuer, E. J., & Thun, M. J. (2004) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.54.1.8 · Cited by 3,984
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.022 · Cited by 1,937
Kabbinavar, F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Lieberman, G., Griffing, S., & Bergsland, E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,716
Prognosis of Cancers Associated with Venous Thromboembolism
Sørensen, H. T., Mellemkjær, L., Olsen, J. H., & Baron, J. A. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012213432504 · Cited by 1,628
Louvet, C., Labianca, R., Hammel, P., Lledo, G., Zampino, M. G., André, T., Zaniboni, A., Ducreux, M., Aitini, E., Taïeb, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.023 · Cited by 950
A Confidence Interval for the Median Survival Time
Brookmeyer, R., & Crowley, J. (1982) · Biometrics · doi:10.2307/2530286 · Cited by 914
Berlin, J. D., Catalano, P., Thomas, J. P., Kugler, J. W., Haller, D. G., & Benson, A. B. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.149 · Cited by 729
Rocha Lima, C. M., Green, M. R., Rotche, R., Miller, W. H., Jeffrey, G. M., Cisar, L. A., Morganti, A., Orlando, N., Gruia, G., & Miller, L. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.12.082 · Cited by 588
Casper, E. S., Green, M. R., Kelsen, D. P., Heelan, R. T., Brown, T. D., Flombaum, C. D., Trochanowski, B., & Tarassoff, P. G. (1994) · Investigational New Drugs · doi:10.1007/bf00873232 · Cited by 435
Seo, Y., Baba, H., Fukuda, T., Takashima, M., & Sugimachi, K. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000515)88:10<2239::aid-cncr6>3.0.co;2-v · Cited by 400
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O’Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.2 · Cited by 344
Prognostic significance of angiogenesis in human pancreatic cancer
Ikeda, N., Adachi, M., Taki, T., Huang, C., Hashida, H., Takabayashi, A., Sho, M., Nakajima, Y., Kanehiro, H., Hisanaga, M., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690248 · Cited by 316
Itakura, J., Ishiwata, T., Friess, H., Fujii, H., Matsumoto, Y., Büchler, M. W., & Korc, M. (1997) · PubMed · Cited by 291
Pancreatic cancer and thromboembolic disease
Khorana, A. A., & Fine, R. L. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01606-7 · Cited by 269
Salvén, P., Orpana, A., & Joensuu, H. (1999) · PubMed · Cited by 252
Itakura, J., Ishiwata, T., Shen, B., Kornmann, M., & Korc, M. (2000) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(20000101)85:1<27::aid-ijc5>3.0.co;2-8 · Cited by 234
Pathways for aberrant angiogenesis in pancreatic cancer.
Korc, M. (2003) · Molecular Cancer · doi:10.1186/1476-4598-2-8 · Cited by 196
Baker, C. H., Solórzano, C. C., & Fidler, I. J. (2002) · PubMed · Cited by 196
Niedergethmann, M., Hildenbrand, R., Wostbrock, B., Hartel, M., Sturm, J. W., Richter, A., & Post, S. (2002) · Pancreas · doi:10.1097/00006676-200208000-00002 · Cited by 191
Marschall, Z. V., Cramer, T., Höcker, M., Burde, R., Plath, T., Schirner, M., Heidenreich, R., Breier, G., Riecken, E., Wiedenmann, B., et al. (2000) · Gastroenterology · doi:10.1053/gast.2000.19578 · Cited by 189
Serum vascular endothelial growth factor is often elevated in disseminated cancer.
Salvén, P., Mänpää, H., Orpana, A., Alitalo, K. K., & Joensuu, H. (1997) · PubMed · Cited by 188
Vessel counts and vascular endothelial growth factor expression in pancreatic adenocarcinoma
Ellis, L. M., Takahashi, Y., Fenoglio, C. J., Cleary, K. R., Bucana, C. D., & Evans, D. B. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(97)10068-5 · Cited by 159
Bruns, C. J., Shrader, M., Harbison, M. T., Portera, C. A., Solórzano, C. C., Jauch, K. ‐., Hicklin, D. J., Radinsky, R., & Ellis, L. M. (2002) · International Journal of Cancer · doi:10.1002/ijc.10681 · Cited by 146
Tsuzuki, Y., Carreira, C. M., Bockhorn, M., Xu, L., Jain, R. K., & Fukumura, D. (2001) · Laboratory Investigation · doi:10.1038/labinvest.3780357 · Cited by 120
Solórzano, C. C., Baker, C. H., Bruns, C. J., Killion, J. J., Ellis, L. M., Wood, J. M., & Fidler, I. J. (2001) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/108497801753354267 · Cited by 118
Luo, J., Guo, P., Matsuda, K., Truong, N., Lee, A., Chun, C. L., Cheng, S., & Korc, M. (2001) · International Journal of Cancer · doi:10.1002/ijc.1202 · Cited by 93
Karayiannakis, A. J., Bolanaki, H., Syrigos, K. N., Asimakopoulos, B., Polychronidis, A., Anagnostoulis, S., & Simopoulos, C. E. (2003) · Cancer Letters · doi:10.1016/s0304-3835(03)00047-8 · Cited by 91
Bockhorn, M., Tsuzuki, Y., Xu, L., Frilling, A., Broelsch, C. E., & Fukumura, D. (2003) · PubMed · Cited by 89
Richards, D., Kindler, H. L., Oettle, H., Ramanathan, R. K., Laethem, J. V., Peeters, M., Fuchs, M., John, W. J., Arning, M., & Hoff, D. D. V. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.4007 · Cited by 74
Self-citationIssues in designing sequential stopping rules for monitoring side effects in clinical trials
Goldman, A. I. (1987) · Controlled Clinical Trials · doi:10.1016/0197-2456(87)90153-x · Cited by 29
Laparoscopic radiofrequency ablation and systemic chemotherapy for colorectal liver metastases
McCain, D. A. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.14_suppl.3776 · Cited by 13
Cited by
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
Influence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
Carey, R. M., Calhoun, D. A., Bakris, G. L., Brook, R. D., Daugherty, S. L., Dennison-Himmelfarb, C. R., Egan, B. M., Flack, J. M., Gidding, S. S., Judd, E., et al. (2018) · Hypertension · doi:10.1161/hyp.0000000000000084 · Cited by 1,153
Pancreatic cancer stroma: an update on therapeutic targeting strategies
Hosein, A. N., Brekken, R. A., & Maitra, A. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-0300-1 · Cited by 950
Kindler, H. L., Niedzwiecki, D., Hollis, D., Sutherland, S., Schrag, D., Hurwitz, H., Innocenti, F., Mulcahy, M. F., O'Reilly, E., Wozniak, T. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1386 · Cited by 845
Self-citation
Metadata
- Authors
- Kindler, H. L., Friberg, G., Singh, D. A., Locker, G., Nattam, S., Kozloff, M., Taber, D. A., Karrison, T., Dachman, A., Stadler, W. M., & Vokes, E. E.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-11-01
- Volume
- 23
- Issue
- 31
- Pages
- 8033-8040
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2124863710
- Cited by
- 460
- References
- 38
- FWCI
- 22.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.